 |
|
|
|
|
Utah Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing UtahLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Q Therapeutics, Inc.
| | | | | Phone: | (801) 582-5400 | | Fax: | (801) 582-5401 | | Year Established: | 2002 | | Main Contact: | Steven J. Borst, President & CEO | | | | Other Contacts: | David A. Green, CPA, CFO
James T. Campanelli, Ph.D., Senior Director, R&D
Mahendra Rao, MD, Ph.D., Co-founder
| | | | Company Description | | Q Therapeutics is engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company’s first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig’s disease), spinal cord injury, Parkinson’s disease and Alzheimer’s disease. Q Therapeutics’ initial clinical target is ALS, with a first IND submission expected in 2013. | |
|
|
|
|
|
|
|
